Utility of SPM8 plus DARTEL (VSRAD) Combined with Magnetic Resonance Spectroscopy as Adjunct Techniques for Screening and Predicting Dementia due to Alzheimer's Disease in Clinical Practice
Utility of SPM8 plus DARTEL (VSRAD) Combined with Magnetic Resonance Spectroscopy as Adjunct Techniques for Screening and Predicting Dementia due to Alzheimer's Disease in Clinical Practice
复制标题
DOI：
10.3233/jad-132786
复制
发表时间：
2014-01-01
影响因子：
4
通讯作者：
Uemura, Kenichi
中科院分区：
文献类型：
--
作者：
Waragai, Masaaki;Hata, Saori;Uemura, Kenichi
我们验证了 SPM8 plusDARTEL (VSRAD) 与磁共振波谱 (H-1 MRS) 相结合作为阿尔茨海默病 (AD) 痴呆症辅助筛查技术的实用性。除了基线时的常规脑脊液生物标志物之外，我们还使用 VSRAD 和 H-1 MRS 检查了 228 名受试者的后扣带回。在3年的随访中，228名受试者被分类为：93名健康受试者、42名MCI未转换者（MCI-NC）、25名MCI转换为AD（MCI-C）、44名AD、8名路易体痴呆（DLB）、5名常压脑积水和11名其他神经系统疾病患者。我们的结果表明，基线时 VSRAD 上内侧颞叶萎缩 (MTA) 严重程度增加、H-1 MRS 上 Cho/Cr、MI/Cr 比值增加以及 H-1 MRS 上 NAA/Cr 和 NAA/MI 比值下降的受试者面临 AD 所致痴呆的风险。受试者操作特征分析表明，MTA 的严重程度和 NAA/MI 比率可将 AD 和 MCI-C 患者与对照组区分开来。此外，118 名没有痴呆和 MTA 的受试者在基线时仅表现出 NAA/MI 比率下降，3 年后发展为 MCI-C、AD 和 DLB。 H-1 MRS 检测到脑萎缩和认知能力下降之前的生化异常。 VSRAD 联合 H-1 MRS 在临床实践中可常规应用于 MCI/AD 和前驱 AD 的筛查。
We validated the utility of SPM8 plusDARTEL (VSRAD) combined with magnetic resonance spectroscopy (H-1 MRS) as an adjunct screening technique for dementia due to Alzheimer's disease (AD). We examined the posterior cingulate gyri of 228 subjects using VSRAD and H-1 MRS in addition to conventional cerebrospinal fluid biomarkers at baseline. At the 3-year follow-up, the 228 subject were classified as follows: 93 healthy subjects, 42 MCI-non-converters (MCI-NC), 25 MCI-converters to AD (MCI-C), 44 AD, 8 dementia with Lewy bodies (DLB), 5 normal pressure hydrocephalus, and 11 patients with other neurological diseases. Our results demonstrated that subjects with increased medial temporal atrophy (MTA) severity on VSRAD, increased Cho/Cr, MI/Cr ratio, and decreased NAA/Cr and NAA/MI ratio on H-1 MRS at baseline were at risk of dementia due to AD. Receiver operating characteristic analysis showed that severity of MTA and the NAA/MI ratio distinguished patients with AD and MCI-C from controls. Furthermore, the 118 subjects without dementia and MTA showing only a decreased NAA/MI ratio at baseline developed to MCI-C, AD, and DLB 3 years later. H-1 MRS detected biochemical abnormalities preceding brain atrophy and cognitive decline. VSRAD combined with H-1 MRS may be routinely applied to screen for MCI/AD and prodromal AD in clinical practice.